Since the new year of 2022, the A-share index has been under pressure, but one stock has been trading daily. As of January 11, Shanghai Kaikai Industry Company Limited(600272) (600272) has been trading for seven consecutive trading days. If the cumulative increase of Shanghai Kaikai Industry Company Limited(600272) has reached 100% since December 30, 2021, the share price has successfully doubled. Behind the sharp rise in share prices, the company has clarified the subjects involved for many times, while hot money has enjoyed “beating drums and passing flowers” to raise share prices in turn.
On December 30, 2021, the scheduled disclosure schedule of the annual report of Shanghai Stock Exchange was released, and Panda Financial Holding Corp.Ltd(600599) and Shanghai Kaikai Industry Company Limited(600272) won the top, both of which will be disclosed on January 28. The next day, the two stocks both rose the limit, and thus opened their trading trip. This is particularly beautiful when the overall market is sluggish in the new year.
On January 5, 2022, Shanghai Kaikai Industry Company Limited(600272) issued a performance pre increase announcement: it is expected that the net profit in 2021 will increase by 6.15 million yuan to 8.89 million yuan compared with the same period of last year, with a year-on-year increase of 45% to 65%. For the reasons for the pre increase of performance, Shanghai Kaikai Industry Company Limited(600272) said that during the reporting period, the company received a total of 12.9 million yuan of government subsidies allocated by superior government departments transferred by the company’s controlling shareholder Shanghai Kaikai (Group) Co., Ltd.
The pre increase of performance is not too high, and most of it comes from non operating profits and losses. Why can Shanghai Kaikai Industry Company Limited(600272) share price rise so strongly? It is rumored that ” Shanghai Kaikai Industry Company Limited(600272) wholly owned subsidiary Shanghai leiyunshang pharmaceutical West Co., Ltd. has the national confidential formula of Liushen Pill”. In this regard, Shanghai Kaikai Industry Company Limited(600272) clarified that the company does not have any national confidential pharmaceutical formula, nor does it have the production business of Liushen Pill. The company does not have any R & D and production of products related to covid-19 repair fluid.
However, Shanghai Kaikai Industry Company Limited(600272) mentioned many times in the interactive and easy response to investors\’ questions that “leiyunshang, the pharmaceutical sector of the company, is mainly engaged in drug circulation, traditional Chinese medicine and pharmaceutical services with the Chinese time-honored brand \’leiyunshang\’ as the brand and the sales of high-end tonics of its own brand ‘shanglei\’, which is a pharmaceutical retail and wholesale enterprise.”
“Recently, the traditional Chinese medicine sector has continued to rise sharply, Shanghai Kaikai Industry Company Limited(600272) although the performance pre increase is not the highest, the superposition of the concept of traditional Chinese medicine and the name of the top in the annual report of Shanghai stock market have attracted a lot of capital attention.” A market person told the reporter of Dazhong securities news. According to the data of the dragon and tiger list, in the seven trading days of the trading limit, institutional special-purpose rarely appeared. Most of the trading seats come from the brokerage business department where hot money is located, and there is a situation of “beating drums and passing flowers”.
From December 30, 2021 to January 4, 2022, Huaxin Securities Shanghai Kaixuan North Road business department bought a net of RMB 7.23 million, and on January 5 and 6, it bought a net of RMB 18.2 million and became the first in the sales list. In these two days, the first place in the buying list was replaced by the China Galaxy Securities Co.Ltd(601881) Securities Beijing Beijing Centergate Technologies (Holding) Co.Ltd(000931) Street business department, with a net purchase of 21.35 million yuan. On January 7, the business department sold a net sales of 25.7062 million yuan, ranking first in the selling list. Business departments such as Huatai Securities Co.Ltd(601688) headquarters, Huatai Securities Co.Ltd(601688) Jiangning Road, Putuo District, Shanghai, Guotai Junan Securities Co.Ltd(601211) securities Kunming Renmin Middle Road, China Galaxy Securities Co.Ltd(601881) Securities Guangzhou Yuejiang middle road all bought on the first day and sold on the second day.
(source: Dazhong Securities Journal)
